Figures computed from official regulatory filings — .
Analysttarget 107.23 USD (+67%) · consensus 4.57/5 · 13 buy · 1 hold · 0 sell
Ownershipinsiders 3.66% · institutions 85.44% · short 9.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ARROWHEAD PHARMACEUTICALS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
34 buys444 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| PERRY MICHAEL S | Sell | $1M | SEC |
| OLUKOTUN ADEOYE Y | Sell | $173.9K | SEC |
| Cohen Matthew Gregory | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lu Hongbotrack record | Sell | $228.3K | SEC |
| Hamilton James C | Sell | $750K | SEC |
| Apel Daniel Joseph | Sell | $627.9K | SEC |
| Apel Daniel Joseph | Sell | $224.9K | SEC |
| Apel Daniel Joseph | Sell | $81.5K | SEC |
| Hamilton James C | Sell | $641.9K | SEC |
| Apel Daniel Joseph | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hamilton James C | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hamilton James C | Sell | $812.9K | Unusual size | SEC |
| Hamilton James C | Sell | $932K | Unusual size | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hamilton James C | Sell | $21K | SEC |
| O'Brien Patrick | Sell | $56K | SEC |
| Hamilton James C | Sell | $283.2K | SEC |
| O'Brien Patrick | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |